Vifor Pharma AG:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10833
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vifor Pharma AG (Vifor Pharma) a subsidiary of Galenica Ltd is a healthcare service provider that discovers, develops, manufactures, and commercializes prescription and over the counter pharmaceutical products for the treatment of iron replacement therapy. The company offers products for treatment of iron deficiency, a range of non prescription products for the treatment of infectious diseases, and iron based phosphate binder for controlling serum phosphorus levels in patients with chronic kidney disease undergoing dialysis. Vifor Pharma’s clinical programs concentrates on safety and efficacy of Broncho Vaxom for respiratory tract infections in children and in chronic obstructive pulmonary disease in adults; and uro vaxom for recurrent urinary tract infections. It has manufacturing facilities in Switzerland, the UK and Portugal. Vifor Pharma is headquartered in Glattbrugg, Switzerland.

Vifor Pharma AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vifor Pharma AG, Medical Devices Deals, 2012 to YTD 2018 10
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Relypsa Secures USD2.6 Million in Venture Funding 13
Relypsa Raises US$80 Million In Series C Financing 14
Relypsa Secures USD62.4 Million in Venture Funding 16
Partnerships 17
Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 17
Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 18
Probi Enters Into Co-Marketing Agreement With Vifor Pharma 19
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 20
Licensing Agreements 21
Vifor-Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with Cara Therapeutics 21
Zeria Pharma Enters into Licensing Agreement with Vifor Pharma 23
Kissei Pharma Enters into Licensing Agreement with Vifor Fresenius Medical Care Renal Pharma 24
Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 25
Vifor Pharma Enters into Licensing Agreement with ChemoCentryx 26
Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 27
Vifor Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with OPKO Health for Rayaldee 28
Vifor Pharma Expands Licensing Agreement with Roche 29
Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 30
Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 31
Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 32
Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 33
Equity Offering 34
Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 34
Relypsa Raises USD172 Million in Public Offering of Shares 35
Relypsa Completes Public Offering Of Shares For US$101.2 Million 37
Relypsa Completes IPO For US$86.7 Million 39
Debt Offering 41
Vifor Pharma Raises USD473.6 Million in Public Offering of 0.75% Bonds Due 2022 41
Acquisition 42
Vifor Pharma to Acquire 14.6% Stake in Chemocentryx from GlaxoSmithKline 42
Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 44
Relypsa May Sell Itself 46
Vifor Pharma AG – Key Competitors 47
Vifor Pharma AG – Key Employees 48
Vifor Pharma AG – Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 51
Financial Announcements 51
Aug 08, 2018: Vifor Pharma Group reports strong H1 2018 results, raises full-year guidance 51
Mar 15, 2018: Vifor Pharma Group Reports Strong 2017 Results, Exceeding Raised Guidance 55
Aug 08, 2017: Vifor Pharma Reports Strong H1 2017 Results And Raises Guidance 60
Corporate Communications 61
Sep 20, 2018: Vifor Pharma announces changes in management 61
Mar 29, 2018: Vifor Pharma to Propose Jacques Theurillat as Board Member 62
Government and Public Interest 63
Feb 20, 2017: Vifor Pharma and ECCO Announces One-Year Research Grant for Iron Deficiency 63
Clinical Trials 64
Feb 08, 2018: Vifor Pharma Ferroportin Inhibitor Enters Phase-I Clinical Trial 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Vifor Pharma AG, Pharmaceuticals & Healthcare, Key Facts 2
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vifor Pharma AG, Deals By Therapy Area, 2012 to YTD 2018 9
Vifor Pharma AG, Medical Devices Deals, 2012 to YTD 2018 10
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Relypsa Secures USD2.6 Million in Venture Funding 13
Relypsa Raises US$80 Million In Series C Financing 14
Relypsa Secures USD62.4 Million in Venture Funding 16
Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 17
Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 18
Probi Enters Into Co-Marketing Agreement With Vifor Pharma 19
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 20
Vifor-Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with Cara Therapeutics 21
Zeria Pharma Enters into Licensing Agreement with Vifor Pharma 23
Kissei Pharma Enters into Licensing Agreement with Vifor Fresenius Medical Care Renal Pharma 24
Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 25
Vifor Pharma Enters into Licensing Agreement with ChemoCentryx 26
Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 27
Vifor Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with OPKO Health for Rayaldee 28
Vifor Pharma Expands Licensing Agreement with Roche 29
Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 30
Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 31
Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 32
Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 33
Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 34
Relypsa Raises USD172 Million in Public Offering of Shares 35
Relypsa Completes Public Offering Of Shares For US$101.2 Million 37
Relypsa Completes IPO For US$86.7 Million 39
Vifor Pharma Raises USD473.6 Million in Public Offering of 0.75% Bonds Due 2022 41
Vifor Pharma to Acquire 14.6% Stake in Chemocentryx from GlaxoSmithKline 42
Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 44
Relypsa May Sell Itself 46
Vifor Pharma AG, Key Competitors 47
Vifor Pharma AG, Key Employees 48
Vifor Pharma AG, Other Locations 49
Vifor Pharma AG, Subsidiaries 49

List of Figures
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vifor Pharma AG, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Vifor Pharma AG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PAREXEL International Corporation:企業の戦略・SWOT・財務分析
    PAREXEL International Corporation - Strategy, SWOT and Corporate Finance Report Summary PAREXEL International Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • TIS Inc (3626):企業の財務・戦略的SWOT分析
    TIS Inc (3626) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Lawson Health Research Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Lawson Health Research Institute (Lawson) is a hospital-based research institute that offers educational and research programs. The institute’ services include health research programs, medical research programs, educational research programs, scientific research programs, patient care servi …
  • Intra-Cellular Therapies Inc (ITCI):企業の財務・戦略的SWOT分析
    Summary Intra-Cellular Therapies Inc (ITI) is a novel drug manufacturer. The company offers product platform such as ITCI Pipeline that includes lumateperone, ITI-007 platform, PDE inhibitor platform and drug discovery platform. The company’s lead product candidate ITI-007-lumateperone is to treat s …
  • Great Panther Silver Limited:企業の戦略・SWOT・財務情報
    Great Panther Silver Limited - Strategy, SWOT and Corporate Finance Report Summary Great Panther Silver Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Yue Yuen Industrial (Holdings) Limited:企業の戦略・SWOT・財務情報
    Yue Yuen Industrial (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Yue Yuen Industrial (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Scotiabank Peru S.A.A.
    Scotiabank Peru S.A.A. - Strategy, SWOT and Corporate Finance Report Summary Scotiabank Peru S.A.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Pedevco Corp (PED):石油・ガス:M&Aディール及び事業提携情報
    Summary Pedevco Corp (Pedevco), formerly Pacific Energy Development Corp is an oil and gas exploration and development company. The company operates in the acquisition and development of energy projects such as shale oil and gas assets. Its oil and gas asset is located in the D-J Basin in Weld and M …
  • China Vanke Co., Ltd.:企業のM&A・事業提携・投資動向
    China Vanke Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Vanke Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Petroleos de Venezuela SA-石油・ガス分野:企業M&A・提携分析
    Summary Petroleos de Venezuela SA (PDVSA) is a state-owned oil and gas company. It plans, coordinates, supervises, and controls the activities in the entire oil and gas value chain. The company explores for and develops oil and other hydrocarbons; refines, trades, and supplies that in domestic and o …
  • Chevron Pipe Line Co:石油・ガス:M&Aディール及び事業提携情報
    Summary Chevron Pipe Line Co (CPL), a subsidiary of Chevron Corp is an oil and gas company that operates, constructs and maintains pipeline systems for fuel transportation. The company owns and operates pipeline assets that transport refined petroleum products, liquefied petroleum gas, natural gas, …
  • Comba Telecom Systems Holdings Limited (2342):企業の財務・戦略的SWOT分析
    Comba Telecom Systems Holdings Limited (2342) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • The Gunma Bank Ltd:企業の戦略・SWOT・財務分析
    The Gunma Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The Gunma Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • G-III Apparel Group, Ltd.:企業の戦略・SWOT・財務分析
    G-III Apparel Group, Ltd. - Strategy, SWOT and Corporate Finance Report Summary G-III Apparel Group, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Indago Energy Ltd (INK):石油・ガス:M&Aディール及び事業提携情報
    Summary Indago Energy Ltd (Indago), formerly Pryme Energy Ltd is a provider of specialist oil and gas production chemicals. The company offers acquisition, up-gradation, exploration and production services to onshore oil and natural gas. It holds interests in the Newkirk project located in Kay Count …
  • Caixa Economica Federal:企業の戦略・SWOT・財務情報
    Caixa Economica Federal - Strategy, SWOT and Corporate Finance Report Summary Caixa Economica Federal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • JK Sucralose Inc.:企業の戦略・SWOT・財務情報
    JK Sucralose Inc. - Strategy, SWOT and Corporate Finance Report Summary JK Sucralose Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Avangrid Renewables LLC:電力:M&Aディール及び事業提携情報
    Summary Avangrid Renewables LLC (Avangrid Renewables) a subsidiary of Avangrid Renewables Holdings, Inc., is a renewable energy company that carries out electricity generation from renewable energy sources including wind, biomass, solar energy and thermal energy. The company also provides services s …
  • Mitsubishi Heavy Industries Ltd (7011):電力:M&Aディール及び事業提携情報
    Summary Mitsubishi Heavy Industries Ltd (MHI) is a manufacturer of heavy machinery. It offers a diverse range of products and services for power plants, chemical plants, environmental equipment, steel structures, industrial and general machinery, shipbuilding, aircraft, space systems and air-conditi …
  • Walgreens Boots Alliance, Inc.:企業の戦略・SWOT・財務情報
    Walgreens Boots Alliance, Inc. - Strategy, SWOT and Corporate Finance Report Summary Walgreens Boots Alliance, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆